Literature DB >> 1914539

Hereditary haemochromatosis in Denmark 1950-1985. Clinical, biochemical and histological features in 179 patients and 13 preclinical cases.

N Milman1.   

Abstract

During the period 1950-1985, a total of 179 cases of clinically overt hereditary haemochromatosis (HH) were registered in Denmark, 140 males and 39 females. Median age at diagnosis was 55 years (range 29-81). Diagnostic approaches, symptoms and physical signs at discovery are described. All patients had grade 3-4 liver haemosiderin iron, and cirrhosis was present in 84%. Serum (S-) transaminase was elevated in 92%, S-alkaline phosphatase in 47% and S-bilirubin in 23%, while plasma prothrombin time was below normal in 34%. Females had higher alkaline phosphatase than males (p less than 0.05). Bone marrow haemosiderin iron (n = 81) showed no relation to iron status indicators and was unsuitable as a diagnostic tool. Skin biopsy (n = 56) was positive for haemosiderin iron in 67% and for melanin in 57%, but was of limited value in the assessment of HH. Arthropathy was registered in 44%; arthralgias and clinical joint abnormalities occurred more frequently in females than in males (p less than 0.05). Latent diabetes mellitus was found in 34% and overt diabetes in 55%, being more frequent in males than in females (p less than 0.05). Other endocrine abnormalities were seen in 66%. Cardiac failure was observed in 9% and abnormal ECG in 35%. Males had higher haemoglobin (p less than 0.0001) and S-iron (p less than 0.01) than females, while S-transferrin, transferrin saturation, S-ferritin and mobilizable iron stores showed no significant sex differences. Median transferrin saturation was 87% (range 52-100); values greater than 62% were observed in 96% of the patients. Median S-ferritin was 3,400 micrograms/l (800-12,700) and median iron stores 14.8 g (4.5-36.4).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1914539

Source DB:  PubMed          Journal:  Dan Med Bull        ISSN: 0907-8916


  8 in total

1.  Relation between bone marrow hemosiderin iron, serum iron status markers, and chemical and histochemical liver iron content in 82 patients with alcoholic and nonalcoholic hepatic disease.

Authors:  N Milman; N Graudal; J Hegnhøj; J Visfeldt; P Christoffersen; N S Pedersen
Journal:  Ann Hematol       Date:  1993-04       Impact factor: 3.673

2.  Frequencies of the hereditary hemochromatosis allele in different populations. Comparison of previous phenotypic methods and novel genotypic methods.

Authors:  Nils Milman; Palle Pedersen; Torkil á Steig; Gitte Vedel Melsen
Journal:  Int J Hematol       Date:  2003-01       Impact factor: 2.490

3.  Transferrin subtypes in 51 Danish patients with hereditary haemochromatosis and in 847 normal subjects.

Authors:  N Milman; H Eiberg; M Thymann; K Fenger
Journal:  Hum Genet       Date:  1992-02       Impact factor: 4.132

4.  Serum or plasma ferritin concentration as an index of iron deficiency and overload.

Authors:  Maria Nieves Garcia-Casal; Sant-Rayn Pasricha; Ricardo X Martinez; Lucero Lopez-Perez; Juan Pablo Peña-Rosas
Journal:  Cochrane Database Syst Rev       Date:  2021-05-24

Review 5.  Diabetes in HFE Hemochromatosis.

Authors:  James C Barton; Ronald T Acton
Journal:  J Diabetes Res       Date:  2017-02-26       Impact factor: 4.011

Review 6.  Diagnosis and Treatment of Genetic HFE-Hemochromatosis: The Danish Aspect.

Authors:  Nils Thorm Milman; Frank Vinholt Schioedt; Anders Ellekaer Junker; Karin Magnussen
Journal:  Gastroenterology Res       Date:  2019-10-04

Review 7.  Abdominal pain and cirrhosis at diagnosis of hemochromatosis: Analysis of 219 referred probands with HFE p.C282Y homozygosity and a literature review.

Authors:  James C Barton; J Clayborn Barton; Neha Patel; Gordon D McLaren
Journal:  PLoS One       Date:  2021-12-21       Impact factor: 3.240

8.  Brain iron loading impairs DNA methylation and alters GABAergic function in mice.

Authors:  Qi Ye; Malav Trivedi; Yiting Zhang; Mark Böhlke; Helal Alsulimani; JuOae Chang; Timothy Maher; Richard Deth; Jonghan Kim
Journal:  FASEB J       Date:  2018-10-02       Impact factor: 5.834

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.